A Pilot Study of In-lab Dynamic Standing in Parkinson's Disease (FOGSTAND)

This research is studying the use of a new type of standing desk in a small number of people to learn about the user experience for people with Parkinson's disease. 12 4-hour sessions will be performed to test the primary hypothesis that dynamic standing improves gait function compared to static standing and control sitting. This study has 2 phases. Phase 1 will be an open-label study and Phase 2 will be an in-lab randomized controlled trial pilot study. This is phase 1 of the study.

Study Overview

• Status: Recruiting
• Conditions: Parkinson Disease
• Intervention / Treatment: Device: Dynamic Standing Desk

Detailed Description

For phase 1, participants will attend up to 12 4-hour sessions using the dynamic standing desk. In addition to these sessions, there will be a clinical assessment at baseline and an outcome session (endpoint assessments). In total, there will be up to 14 sessions per participant. All sessions need to be completed within 6 weeks. At the baseline session, clinical measurements will be collected. These measures will be repeated in the outcome session.

• Study Type: Interventional
• Enrollment (Estimated): 5
• Phase: Phase 1

Contacts and Locations

• Study Contact: Name: Miriam Van Emde Boas, DPT; Phone Number: 734-936-1174; Email: bohnenmi@med.umich.edu
• Study Contact Backup: Name: Chatkaew Pongmala, PhD; Phone Number: 734-936-0111; Email: pchatkae@med.umich.edu

Study Locations

• United States
  • Michigan
    • Ann Arbor, Michigan, United States, 48105
      • Recruiting
      • Domino's Farms
      • Contact: Miriam Bohnen, DPT; Phone Number: 734-936-1174; Email: bohnenmi@med.umich.edu

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Diagnosis of Parkinson's Disease

Exclusion Criteria:

• Inability to stand or walk without an assistive device
• History of symptoms in stance that preclude safe and comfortable participation, such as dizziness and lightheadedness, orthostasis, severe symptomatic leg or back musculoskeletal pain, or medication side effects
• Any other history of medical or psychiatric comorbidity, precluding safe participation in the project.
• History of symptomatic cardiovascular or pulmonary disease
• History of active rheumatic arthritis
• History of stroke or other neurologic conditions with significant residual sensorimotor deficits
• History of disabling chronic pain syndrome requiring narcotic analgesics
• Evidence of dementia (Mini Mental State Exam (or Montreal Cognitive Assessment test) <24 and significant impairment in activities of daily living)
• Venous ulcerative stasis or severe varicosities.
• Pregnancy as determined by urine pregnancy test prior to DXA procedure in women of childbearing potential.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Dynamic Standing Desk in People with Parkinsons; Up to 12 4-hour sessions with the dynamic standing desk completed in the span of 6 weeks.	Device: Dynamic Standing Desk; Participants will stand at the desk for 4 hours per session. During each session, the desk will move to prompt the participant to take small steps. Participants will take breaks as needed. Each participant will complete up to 12 sessions in the span of 6 weeks.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Gait Speed	Gait speed will be measured during an 8.5-meter forward walking task measured in meters per second.	Baseline and post-intervention (up to 6 weeks).
Movement Disorder Society-Unified Parkinson's Disease Rating Scale Part III	Clinical assessment that measures motor symptoms in Parkinson's Disease. Higher scores indicates more severe symptoms. Scores range from 0-132.	Baseline and post-intervention (up to 6 weeks).
Montreal Cognitive Assessment	Clinical assessment that measures cognition. Higher scores indicate better cognition. Scores range from 0-30.	Baseline and post-intervention (up to 6 weeks).
Timed Up and Go	Clinical assessment that measures the time it takes for a participant to stand from a chair, walk 3 meters, turn around, walk back to the chair and sit back down. Higher time indicates increased motor impairment.	Baseline and post-intervention (up to 6 weeks).
5 Times Sit to Stand	Clinical assessment that measures the time it takes for a participant to sit and stand five times. Higher time indicates increased motor impairment.	Baseline and post-intervention (up to 6 weeks).

Collaborators and Investigators

• Sponsor: University of Michigan
• Investigators: Principal Investigator: Chatkaew Pongmala, PhD, University of Michigan

Study record dates

Study Major Dates

• Study Start (Actual): May 15, 2026
• Primary Completion (Estimated): March 1, 2027
• Study Completion (Estimated): March 1, 2027

Study Registration Dates

• First Submitted: April 7, 2026
• First Submitted That Met QC Criteria: April 14, 2026
• First Posted (Actual): April 22, 2026

Study Record Updates

• Last Update Posted (Actual): August 14, 2026
• Last Update Submitted That Met QC Criteria: August 11, 2026
• Last Verified: August 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Synucleinopathies; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Neurodegenerative Diseases; Movement Disorders; Parkinsonian Disorders; Basal Ganglia Diseases; Parkinson Disease
• Other Study ID Numbers: HUM00280455

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: Yes
• product manufactured in and exported from the U.S.: No